Development of a Predictive Model for Prostate Cancer Using a Machine Learning Based Classification Algorithm
Article Sidebar
Main Article Content
Prostate cancer remains one of the most prevalent malignancies among men worldwide, with early detection being crucial for effective treatment and improved survival outcomes. Traditional diagnostic procedures, such as prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and biopsy, often suffer from limitations including subjectivity, low specificity, and inconsistent accuracy. This study presents the development of a predictive model for prostate cancer using a machine learning-based classification algorithm, specifically the Support Vector Machine (SVM). The dataset utilised was obtained from a publicly available prostate cancer repository, containing relevant biomedical and demographic features. Preprocessing procedures, including normalisation and data transformation, were applied to enhance model quality and ensure robustness. Experimental results revealed that the SVM model achieved a high predictive accuracy of 84.8% under crossvalidation and 87% on full dataset evaluation, with a corresponding error rate of less than 0.17. These results demonstrate the model’s ability to accurately distinguish between malignant and non-malignant cases, validating its suitability for clinical decision support. The model’s performance further confirms the potential of SVM as an effective classification technique for medical diagnostics, especially where datasets exhibit complex, nonlinear feature interactions. This study emphasises the significance of machine learning in enhancing diagnostic precision and reliability within the medical domain. The outcomes provide valuable insights into integrating artificial intelligence into healthcare systems for early cancer detection, reducing diagnostic delays, and supporting medical professionals in clinical decision-making.
Downloads
References
E. Zhang and X. Xiang, “Inference-based Naïve Bayes: Turning Naïve Bayes cost-sensitive,” IEEE Transactions on Knowledge and Data Engineering, vol. 25, pp. 2302–2314, 2013, doi: 10.1109/TKDE.2010.49.
R. C. Huang and C. Lin, “Generalized Bradley–Terry models and multi-class probability estimates,” Journal of Machine Learning Research, vol. 7, pp. 85–115, 2021. [Online]. Available: http://portal.acm.org/citation.cfm?id=1248551
E. T. Mohammed, “Internet traffic classification by aggregating correlated Naïve Bayes predictions,” IEEE Transactions on Information Forensics and Security, pp. 5–15, 2020. [Online]. Available: http://dblp.uni-trier.de/db/journals/tifs/tifs8.html
O. K. Akinsola, H. Wookjoo, and J. Beom, “On the effectiveness of discretizing quantitative attributes in linear classifiers,” Journal of Machine Learning Research, vol. 1, pp. 1–28, 2017.
H. Canfield, J. Zhang, J. C. Yang, N. Milton, and A. D. Alcántara, “An explanatory analysis of driver injury severity in rear-end crashes using a decision table/Naïve Bayes (DTNB) hybrid classifier,” Accident Analysis and Prevention, vol. 90, pp. 95–107, 2019, doi: 10.1016/j.aap.2016.02.002.
Abdel-Zaher and A. Eldeib, “Evolutionary computational methods for optimizing the classification of sea stars in cancerous diseases,” in Proc. IEEE Winter Conf. Appl. Comput. Vis. Workshops (WACVW), 2015, pp. 44–50, doi: 10.1109/WACVW.2015.9.
J. Abdelhamied, “Multi-feature prostate cancer subset selection with K-neighbours classifier,” Knowledge-Based Systems, vol. 55, pp. 110–127, 2018, doi: 10.1016/j.knosys.2013.10.019.
J. A. Bermejo, “Speeding up incremental wrapper feature subset selection with Naïve Bayes classifier,” Knowledge-Based Systems, vol. 55, pp. 140–147, 2020, doi: 10.1016/j.knosys.2013.10.016.
Mahammad and A. Roventa, “Computerized radiographic mass detection,” Knowledge-Based Systems, pp. 140–147, 2019, doi: 10.1016/j.knosys.2013.10.016.
S. Samy and N. Naser, “Prostate-specific antigen–based prostate cancer screening: Reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer,” European Urology, vol. 65, pp. 329–336, 2014.
Klein, “A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer,” Reviews in Urology, vol. 16, no. 4, pp. 172–180, 2014.
J. Wein, L. R. Kavoussi, A. W. Partin, and C. A. Peters, Urology, 10th ed. Philadelphia, PA: Elsevier, 2012.
F. Priya, “Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT),” JAMA, vol. 306, no. 14, pp. 549–556, 2011.
J. Simon, “The effect of dietary and exercise interventions on body weight in prostate cancer patients: A systematic review,” Nutrition and Cancer, vol. 67, no. 1, pp. 43–60, 2020.
O. J. Osisanwo and I. Thompson, “The influence of finasteride on the development of prostate cancer,” New England Journal of Medicine, vol. 349, pp. 215–224, 2019.
K. Hernández, “Contemporary evaluation of the D’Amico risk classification of prostate cancer,” Urology, vol. 70, no. 5, pp. 931–935, 2007.
H. Wookjoo and J. Beom, “On the effectiveness of machine learning technique attributes in linear classifiers,” Journal of Machine Learning Research, vol. 1, pp. 1–28, 2018.
T. Ertosun and Y. F. Rubin, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2020.
L. P. Sadhana, C. H. Bangma, and G. Leenders, “Prostate-specific antigen–based prostate cancer screening: Reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer,” European Urology, vol. 65, pp. 329–336, 2014.
B. Roventa, M. J. Alvarez, L. J. Martinez, and M. Saiz, “Prognostic role of genetic biomarkers in clinical progression of prostate cancer,” Experimental and Molecular Medicine, vol. 47, p. e176, 2022, doi: 10.1038/emm.2015.43.
S. E. Qeethara-Kadhim, A. S. Kibel, and M. J. Kemeter, “A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer,” Reviews in Urology, vol. 16, no. 4, pp. 172–180, 2018.
J. Freasier, A. Heindenreich, P. J. Bastian, J. Bellmunt, and M. Bolla, “EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013,” European Urology, vol. 65, no. 1, pp. 124–137, 2019.
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in our journal are licensed under CC-BY 4.0, which permits authors to retain copyright of their work. This license allows for unrestricted use, sharing, and reproduction of the articles, provided that proper credit is given to the original authors and the source.